A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia.
Wang J, Fabi S, Robinson D, Bajaj S, Geronemus R, Bell M, Widgerow A. A Multi-Center, Randomized, Blinded Clinical Study Evaluating the Efficacy and Safety of a Novel Topical Product for Facial Dyschromia. Journal Of Drugs In Dermatology 2023, 22: 333-338. PMID: 37026875, DOI: 10.36849/jdd.7340.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, CutaneousDermatologic AgentsHumansHydroquinonesHyperpigmentationMelanosisTreatment OutcomeConceptsModified Melasma Area Severity IndexHydroquinone 4%Post-inflammatory hyperpigmentationFacial dyschromiaBlinded clinical studyFollow-upClinical studiesTopical productsAdverse eventsModified melasma area severity index scoreMulti-centerMelasma Area Severity IndexArea Severity IndexNo adverse eventsClearance of pigmentIn vitro studiesExcessive sun exposureBlinded investigatorRight cheekWeek 4Griffiths ScalesReduced clearanceSun exposureMedical disordersTolerability assessments
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply